Let's hope they don't make the same mistake in the clinic!
Experimental: Arm II (PI3K gene mutation)Patients receive PI3K inhibitor GDC-0084 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. https://clinicaltrials.gov/ct2/show/NCT03994796
Description of TreatmentPatients will be randomized into one of three groups. Those in Group 1 (CDK gene mutation) will receive abemaciclib orally twice daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Those in Group 2 (PI3K gene mutation) will receive PI3K inhibitor GDC-0084 orally once daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Those in Group 3 (NTRK/ROS1 gene mutation) will receive entrectinib orally once daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=/Public/News-Genetic-Nov2019
- Forums
- ASX - By Stock
- KZA
- Across the pond...Nasdaq: KZIA
Across the pond...Nasdaq: KZIA, page-236
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online